Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 5/2010

01-09-2010 | Clinical Trial Report

Oral Disease-Modifying Therapies for Multiple Sclerosis: Are We There Yet?

Authors: Vijayshree Yadav, Dennis Bourdette

Published in: Current Neurology and Neuroscience Reports | Issue 5/2010

Login to get access

Excerpt

Kappos L, Radue EW, O’Connor P, et al.; FREEDOMS Study Group: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362:387–401. …
Literature
1.
Kappos L, Radue EW, O’Connor P, et al.: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362:387–401.CrossRefPubMed
2.
Cohen JA, Barkhof F, Comi G, et al.: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010, 362:402–415.CrossRefPubMed
3.
Giovannoni G, Comi G, Cook S, et al.: A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010, 362:416–426.CrossRefPubMed
4.
Chun J, Hartung HP: Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010, 33:91–101.CrossRefPubMed
5.
Comi G, O’Connor P, Montalban X, et al.: Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 2010, 16:197–207.CrossRefPubMed
Metadata
Title
Oral Disease-Modifying Therapies for Multiple Sclerosis: Are We There Yet?
Authors
Vijayshree Yadav
Dennis Bourdette
Publication date
01-09-2010
Publisher
Current Science Inc.
Published in
Current Neurology and Neuroscience Reports / Issue 5/2010
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-010-0126-2

Other articles of this Issue 5/2010

Current Neurology and Neuroscience Reports 5/2010 Go to the issue

ReviewPaper

What Can We Learn From Freezing of Gait in Parkinson’s Disease?

ReviewPaper

Hormonal Influences on Cognition and Risk for Alzheimer’s Disease

ReviewPaper

Physical Activity and Mild Cognitive Impairment and Alzheimer’s Disease

Clinical Trial Report

Tarenflurbil in Patients with Mild Alzheimer’s Disease

ReviewPaper

Multiple Sclerosis and Vitamin D: A Review and Recommendations

ReviewPaper

An Update on the Neurologic Applications of Botulinum Toxins